t cells in rheumatoid arthritist细胞在类风湿性关节炎.pdfVIP

Available online /supplements/10/S1/S1 Review T cells in rheumatoid arthritis Andrew P Cope The Kennedy Institute of Rheumatology, Faculty of Medicine, Imperial College London, Aspenlea Road, Hammersmith, London, W6 8LH, UK Corresponding author: Andrew P Cope, andrew.cope@imperial.ac.uk Published: 15 October 2008 Arthritis Research Therapy 2008, 10(Suppl 1):S1 (doi:10.1186/ar2412) This article is online at /supplements/10/S1/S1 © 2008 BioMed Central Ltd Abstract outcome and to select the most appropriate therapy for our Over the past decade and a half, advances in our understanding of patients. the pathogenesis of immune-mediated diseases such as rheuma- toid arthritis (RA) have translated directly into benefit for patients. Diseases such as RA, but also inflammatory bowel disease Much of this benefit has arisen through the introduction of targeted and psoriasis, are better characterized as a group of proto- biological therapies. At the same time, technological advances typic chronic inflammatory diseases. The most convincing have made it possible to define, at the cellular and molecular levels, evidence for such a notion comes directly from the clinic, in the key pathways that influence the initiation and persistence of chronic inflammatory autoimmune reactions. As our understanding particular the striking clinical responses to anticytokine grows, it is likely that this knowledge will be translated into a biological therapy [2]. Finally, RA is somewhat distinct from seco